Dyne Therapeutics (DYN) CFO Erick Lucera Sells $48K of Stock
Chief Financial Officer Erick Lucera parted with 2,362 shares of Dyne Therapeutics in a late-June transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Erick Lucera, Chief Financial Officer at Dyne Therapeutics, Inc. ($DYN), sold 2,362 shares at an average price of $20.37, worth about $48,113.94, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $DYN is up 11.9% after 1 week, up 24.4% after 1 month and down 30.9% to date (from the $20.61 close on Jun 25, 2026).
DYN
Dyne Therapeutics, Inc.
Key Points
- Dyne Therapeutics, Inc. (NasdaqGS: DYN) Chief Financial Officer Erick Lucera sold 2,362 shares on June 25, 2026, at an average price of $20.37, total value $48,113.94.
- The stock traded near $20.94 recently, sitting above its 200-day moving average of $19.78.
- Analysts maintain a strong buy consensus with a mean price target of $37.20 across 15 opinions.
Get $DYN trade alerts by text
We text you when insiders, Congress or big funds trade $DYN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Dyne Therapeutics, Inc. alert may contain errors. Disclosures
Chief Financial Officer Erick Lucera Sells Shares of Dyne Therapeutics
Dyne Therapeutics, Inc. (NasdaqGS: DYN) Chief Financial Officer Erick Lucera sold 2,362 shares of the company on June 25, 2026. The transaction took place at an average price of $20.37 per share, resulting in a total value of $48,113.94. This sale followed other insider transactions at the biotechnology firm during a busy month of June.
Recent Insider Transactions at Dyne Therapeutics
Insider selling has been active at the company through late June. Other insiders including Jason Rhodes and Dirk Kersten executed multiple planned sales during the same week. Jason Rhodes sold 309,268 shares on June 26, 2026, for about $6.58 million, following earlier sales of 147,760 shares on June 23, 95,900 shares on June 24, and 24,100 shares on June 25. Dirk Kersten also sold 190,676 shares on June 22 for roughly $3.92 million and 46,901 shares on June 18 for $941,303.07. Insider sales do not automatically signal a bearish outlook, as executives often sell for personal financial planning or under scheduled plans.
Dyne Therapeutics Stock Trades Above 200-Day Average
Dyne Therapeutics shares changed hands around $20.94 recently. The stock holds a 50-day moving average of $23.85 and a 200-day moving average of $19.78, with a 52-week trading range between $11.92 and $27.30. The company carries a market capitalization of roughly $3.2 billion and a beta of 1.08.
Analysts Set New Price Targets
Wall Street firms maintain broad coverage of the stock with 15 analyst opinions currently registered. The consensus points to a strong buy rating, supported by a mean price target of $37.20. Recent notes include Chardan Capital maintaining a buy rating with a $38.0 target on September 30, 2026, and HC Wainwright & Co. maintaining a buy rating with a $32.0 target on the same day. Piper Sandler reiterated an overweight rating at a $47.0 target on September 29, 2026.
Building Muscle Disease Treatments
Dyne Therapeutics is a clinical-stage biotech firm based in Waltham, Massachusetts, focused on developing therapeutics for neuromuscular diseases like myotonic dystrophy type 1, duchenne muscular dystrophy, and Pompe disease. The company relies on its proprietary FORCE platform to deliver targeted muscle treatments.
What to Watch at Dyne Therapeutics, Inc.
Investors will look toward the company's next earnings report, scheduled for November 5, 2026, for updates on its clinical pipeline and financial position. Additional regulatory filings will continue to track any further insider transactions.
Related Filing Alerts
Source: Erick Lucera's Form 4 filing on $DYN (Jun 25, 2026). Find the original filing: DYN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts